PRKAR1A Recombinant Monoclonal Antibody

說明書

中文名稱：

PRKAR1A重組抗體
貨號：

CSB-RA018694A0HU
規(guī)格：

￥1320
圖片：
Western Blot
Positive WB detected in: U87 whole cell lysate
All lanes: PRKAR1A antibody at 1.1μg/ml
Secondary
Goat polyclonal to rabbit IgG at 1/50000 dilution
Predicted band size: 43, 39 KDa
Observed band size: 43 KDa

Immunofluorescence staining of Hela cells with CSB-RA018694A0HU at 1:36, counter-stained with DAPI. The cells were fixed in 4% formaldehyde, permeabilized using 0.2% Triton X-100 and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4℃. The secondary antibody was Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG (H+L).
其他：

產(chǎn)品詳情
產(chǎn)品評價
相關(guān)產(chǎn)品
靶點(diǎn)詳情

產(chǎn)品詳情

產(chǎn)品描述：

CSB-RA018694A0HU PRKAR1A重組單克隆抗體是針對蛋白激酶A調(diào)節(jié)亞基1α（PRKAR1A）研發(fā)的高特異性檢測工具。該抗體靶向的PRKAR1A是cAMP依賴性蛋白激酶（PKA）的核心調(diào)節(jié)組分，參與調(diào)控細(xì)胞增殖、分化及代謝等關(guān)鍵生物學(xué)過程，其異常表達(dá)與心臟功能異常、內(nèi)分泌系統(tǒng)腫瘤等病理機(jī)制密切相關(guān)。經(jīng)嚴(yán)格驗證，本產(chǎn)品在Western Blot實驗中可呈現(xiàn)單一清晰條帶，在免疫熒光技術(shù)中能精準(zhǔn)定位細(xì)胞內(nèi)源性蛋白表達(dá)，推薦使用稀釋度為WB 1:500-1:5000、IF 1:20-1:200，并在ELISA平臺展示出色檢測靈敏度。其重組單克隆特性確保了批次間的高度一致性，適用于探究PRKAR1A在cAMP-PKA信號轉(zhuǎn)導(dǎo)、激素調(diào)控及腫瘤微環(huán)境中的功能研究，可為心血管疾病、內(nèi)分泌失調(diào)相關(guān)的基礎(chǔ)研究提供可靠工具，滿足細(xì)胞水平定位分析、蛋白表達(dá)定量及分子互作研究等多元實驗需求。
Uniprot No.：

P10644
基因名：

PRKAR1A
別名：

ACRDYS1 antibody; ADOHR antibody; cAMP dependent protein kinase regulatory subunit alpha 1 antibody; cAMP dependent protein kinase regulatory subunit RIalpha antibody; cAMP dependent protein kinase type I alpha regulatory chain antibody; cAMP dependent protein kinase type I alpha regulatory subunit antibody; cAMP-dependent protein kinase type I-alpha regulatory subunit antibody; CAR antibody; Carney complex type 1 antibody; CNC 1 antibody; CNC antibody; CNC1 antibody; DKFZp779L0468 antibody; KAP0_HUMAN antibody; MGC17251 antibody; PKA RIA antibody; PKR 1 antibody; PKR1 antibody; PPNAD 1 antibody; PPNAD1 antibody; PRKAR 1 antibody; PRKAR1 antibody; PRKAR1A antibody; PRKAR1A/RARA FUSION GENE antibody; Protein kinase A type 1a regulatory subunit antibody; Protein kinase cAMP dependent regulatory type I alpha antibody; PTC2 CHIMERIC ONCOGENE; INCLUDED antibody; Tissue specific extinguisher 1 antibody; Tissue-specific extinguisher 1 antibody; TSE 1 antibody; TSE1 antibody
反應(yīng)種屬：

Human
免疫原：

A synthesized peptide derived from human PRKAR1A
免疫原種屬：

Homo sapiens (Human)
標(biāo)記方式：

Non-conjugated
克隆類型：

Monoclonal
抗體亞型：

Rabbit IgG
純化方式：

Affinity-chromatography
克隆號：

1C3
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Rabbit IgG in 10mM phosphate buffered saline , pH 7.4, 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol.
產(chǎn)品提供形式：

Liquid
應(yīng)用范圍：

ELISA, WB, IF

推薦稀釋比：

Application	Recommended Dilution
WB	1:500-1:5000
IF	1:20-1:200

Protocols：

ELISA Protocol
Western Blotting (WB) Protocol
Immunofluorescence (IF) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評價

靶點(diǎn)詳情

功能：

Regulatory subunit of the cAMP-dependent protein kinases involved in cAMP signaling in cells.
基因功能參考文獻(xiàn)：
1. In Pseudohypoparathyroidism, mutations were found in PRKAR1A, PDE4D, TRPS1, and PTHLH. PMID: 29499646
2. A report of the occurrence of an aberrant serotonergic regulatory loop in primary pigmented nodular adrenocortical disease tissues from patients with PRKAR1A mutations. PMID: 27699247
3. Splice site mutation of the PRKAR1A gene is associated with Carney complex. PMID: 29318463
4. PRKAR1A is a potent tumor suppressor that inhibits the ERK/Snail/E-cadherin pathway in lung adenocarcinoma PMID: 27995993
5. t-Darpp phosphorylation at T39 seems to be crucial for t-Darpp-mediated PKA activation and this activation appears to occur through an association with RI and sequestering of RI away from PKAc. The t-Darpp-RI interaction could be a druggable target to reduce PKA activity in drug-resistant cancer. PMID: 28867659
6. the T allele of SNP rs60684937 located at 67,419,130 bp on chromosome 17 was associated with increased plasma EPO and a relatively increased expression of a non-coding transcript of PRKAR1A in sickle cell disease patients PMID: 28173069
7. In this study we demonstrate a new role of MRAP2 in the regulation of the orexin receptor 1 (OX1R) and identify the specific regions of MRAP2 required for the regulation of OX1R and PKR1. Importantly, like MC4R and PKRs, OX1R is predominately expressed in the brain where it regulates food intake PMID: 28939058
8. Screening of PRKAR1A and PDE4D in a Large Italian Series of Patients Clinically Diagnosed With Albright Hereditary Osteodystrophy and/or Pseudohypoparathyroidism PMID: 26763073
9. we used next-generation sequencing to assess 480 cancer-related genes and performed immunohistochemistry on 13 cases morphologically consistent with pigmented epithelioid melanocytoma. These results further validate the concept of pigmented epithelioid melanocytoma as a distinctive intermediate/borderline melanocytic tumor, and also illustrate its molecular heterogeneity PMID: 28796000
10. Found evidence for kidney and liver cystic phenotypes in the Carney complex, a tumoral syndrome caused by mutations in PRKAR1A. PMID: 28615245
11. Data suggest that introduction of cGMP-specific residues using site-directed mutagenesis reduces selectivity of cyclic nucleotide-binding domain (CNBD) of PRKAR1A; combination of two mutations (G316R/A336T) results in a cGMP-selective binding site in the C-terminal CNBD; introduction of corresponding mutations (T192R/A212T) into the N-terminal CNBD results in a highly cGMP-selective binding site. PMID: 28583991
12. Data show that ELOVL7, SOCS3, ACSL4 and CLU were upregulated while PRKAR1A and ABCG1 were downregulated in the phlegm-dampness group. PMID: 27928700
13. Electrostatic interactions are mediators in the allosteric activation of protein kinase A RIalpha. PMID: 28221775
14. The obtained data on the mechanism of cAMP-dependent activation of PKA I alpha may contribute to new approaches to designing pharmaceuticals based on cAMP analogs. PMID: 28367443
15. the present study reported for the first time an intronic splice site mutation in the PRKAR1A gene of a Chinese family with Carney complex, which probably caused skin pigmentation observed in affected family members. PMID: 26788925
16. This study reports a novel point mutation of the PRKAR1A gene in a patient with Carney complex who presented with significant osteoporosis and fractures. PMID: 27377598
17. Letter/Case Report: novel PRKAR1A mutation resulting in a splicing variant in a case of Carney complex. PMID: 26354069
18. P-Rex1 contributes to the spatiotemporal localization of type I PKA, which tightly regulates this guanine exchange factor by a multistep mechanism. PMID: 26797121
19. In the absence of a PRKAR1A gene mutation, our Cushing's syndrome patients do not fit the criteria for Carney's complex PMID: 26619967
20. Case Report: although there was no family history of any of the Carney complex features and no mutations in the PRKAR1A gene were found, findings lead to the diagnosis of sporadic Carney complex. PMID: 25576349
21. this study evaluated the functional characteristics of PRKAR1A regulatory subunits carrying eight different mutations identified in patients with acrodysostosis and compared the results with those obtained for the two alternative mutations involved in the Carney complex PMID: 26405036
22. PRKAR1A gene and its locus are altered in mixed odontogenic tumors. Expression is decreased in a subset of tumors, and Prkar1a(+) (/) (-) mice do not show abnormalities, which indicates that additional genes play a role in this tumor's pathogenesis. PMID: 25870248
23. The truncated enzyme lacks the functional cyclic adenosine monophosphate (cAMP) binding domain at the C-terminus, causing PRKAR1A haploinsufficiency. PMID: 26416542
24. PRKAR1A gene mutation of c.491_492delTG is associated with multiple and extensive cardiac myxomas and skin pigmentation. PMID: 25890363
25. our data shows that an increased PRKAR1A expression is associated with aggressive and undifferentiated thyroid tumors PMID: 25393625
26. Protein Kinase A Opposes the Phosphorylation-dependent Recruitment of Glycogen Synthase Kinase 3beta to A-kinase Anchoring Protein 220. PMID: 26088133
27. Although the depletion of PRKAR1A and PRKAR2B in adrenocortical cells has similar effects on cell proliferation and apoptosis; loss of these PKA subunits differentially affects cyclin expression. PMID: 25268545
28. Results show that mouse Prkar1a and human PRKAR2A exhibited a dynamic spatio-temporal expression in tooth development, whereas neither human PRKAR1A nor mouse Prkar2a showed their expression in odontogenesis. PMID: 24755349
29. A Carney complex-related pituitary adenoma with a somatic mutation and a large inherited deletion of the PRKAR1A gene was identified. PMID: 25336503
30. we conclude that PRKAR1A mutations may play no major role in the pathogenesis of BDE. PMID: 23425300
31. These results show that RIalpha inactivation leads to multiple, compartment-specific alterations of the cAMP/PKA pathway revealing new aspects of signaling dysregulation in tumorigenesis. PMID: 24122441
32. PRKAR1A appears to play a role in the development of both syndromic and nonsyndromic cardiac myxomas PMID: 24618615
33. Mutagenesis of residues on Protein Kinase A RIalpha interface not only leads to structural and biochemical changes, but is also linked to Carney complex disease. PMID: 24316401
34. Increased PKA signaling in perirenal adipose tissue was associated with lower BMI in Cushing syndrome. Differences in fat distribution may contribute to phenotypic differences between patients with Cushing syndrome with and without PRKAR1A mutations. PMID: 24248186
35. A significant number (21.6%) of patients with Carney complex that are negative in currently available testing may have PRKAR1A haploinsufficiency due to genomic defects that are not detected by Sanger sequencing. PMID: 24170103
36. Data suggest that gene rearrangement in PRKAR1A can result in Carney complex; a large in-frame deletion of exons 3-6 has been identified in three members of a Portuguese family; the truncated PRKAR1A produced in these subjects is unstable. PMID: 24144965
37. Data suggest that protein kinase A enzymatic activity in parathyroid adenoma is less than in normal glands; however, 5 out of 8 parathyroid adenoma tissues expressed higher content of PKA-RIalpha protein as compared with normal parathyroid tissues. PMID: 23197043
38. Evidence for a new mechanism by which hypercapnia via soluble adenylyl cyclase, cAMP, PKA Type Ialpha, and alpha-adducin regulates Na,K-ATPase endocytosis in alveolar epithelial cells. PMID: 23349050
39. REVIEW: Prkar1a in the regulation of insulin secretion PMID: 22951902
40. RIaalpha and RIIaalpha were identified as cCMP-binding proteins. PMID: 22808067
41. Phenotypic differences, including the presence of resistance to GPCR-cAMP signaling hormones in PRKAR1A but not PDE4D patients, indicate phenotype-genotype correlations and highlight the specific contributions of PRKAR1A and PDE4D in cAMP signaling. PMID: 23043190
42. Epithelioid and fusiform blue nevus of chronically sun-damaged skin is a unique subtype of blue nevus without loss of PRKAR1A expression. PMID: 22892599
43. PRKAR1A overexpression is associated with increased ECPKA autoantibody in liver fluke-associated cholangiocarcinoma. PMID: 22922884
44. PRKAR1A mutational analysis and PKA enzymatic activity in endometrial tumors. PMID: 22461635
45. PRKAR1A mutation is associated with Carney complex. PMID: 22297707
46. We treated a 40-year-old man who presented with an embolic stroke. He had a family history of cardiac myxoma and underwent resection of a right atrial myxoma 7 years ago. Genetic evaluation revealed a heterozygous mutation in the PRKAR1A gene. PMID: 22632512
47. Protein kinase A 1 selectively regulates Kv1.3 channels in human T lymphocytes. PMID: 22378744
48. This was the first demonstration of proteasomal degradation of RIalpha protein variants leading to PRKAR1A haploinsufficiency and Carney complex, adding protein surveillance to nonsense mRNA decay in the cellular mechanisms overseeing RIalpha synthesis. PMID: 22205709
49. Data suggest that not all cAMP activation is the same; adrenal lesions harboring PRKAR1A or GNAS mutations share downstream activation of certain oncogenic signals (such as MAPK and cell cycle genes) but differ substantially in effects on others. PMID: 22259056
50. A novel PRKAR1A mutation in Korean Carney complex family. PMID: 22020668
顯示更多

收起更多
相關(guān)疾病：

Carney complex 1 (CNC1); Intracardiac myxoma (INTMYX); Primary pigmented nodular adrenocortical disease 1 (PPNAD1); Acrodysostosis 1, with or without hormone resistance (ACRDYS1)
亞細(xì)胞定位：

Cell membrane.
蛋白家族：

CAMP-dependent kinase regulatory chain family
組織特異性：

Four types of regulatory chains are found: I-alpha, I-beta, II-alpha, and II-beta. Their expression varies among tissues and is in some cases constitutive and in others inducible.
數(shù)據(jù)庫鏈接：

HGNC: 9388

OMIM: 101800

KEGG: hsa:5573

STRING: 9606.ENSP00000351410

UniGene: Hs.280342

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human